Vireo Growth (VREOF) Long-Term Investments (2025 - 2026)
Vireo Growth's (VREOF) quarterly Long-Term Investments came in at $6.0 million in Q1 2026, little changed quarter-over-quarter from $6.0 million in Q4 2025.
Vireo Growth (VREOF) Long-Term Investments (2025 - 2026) Analysis & Trends
Vireo Growth has disclosed Long-Term Investments across 2 years of filings, most recently posting $6.0 million for Q1 2026.
- Long-Term Investments for Q1 2026 came in at $6.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $6.0 million (changed N/A YoY), and the FY2025 annual result was $6.0 million, changed N/A from the prior year.
- Long-Term Investments came in at $6.0 million for Q1 2026 at Vireo Growth, roughly flat from $6.0 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $13.1 million in Q2 2025 to a low of $6.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 1.32 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.33 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 26.36 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.90 Mn |
| 10 | Vireo Growth | - | - | 59.30 Mn | 6.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.00 Mn |
| Dec 31, 2025 | 6.00 Mn |
| Sep 30, 2025 | 6.00 Mn |
| Jun 30, 2025 | 13.10 Mn |